ScienceGuy did you read the study that yada linked on page 2. It seems to suggest that there is in fact a low probability of neurotoxicity at nootropic doses. Why still discuss neurotoxicity?
It's worth mentioning because it be best not combine IDRA-21 with any other glutamate precursors or stimulants. Actually you would want to add some neuroprotective compound to be on the safe side.
Yadayada was kind enough to answer your question for me; wherein, his answer absolutely hits the nail on the head
And yes, I have indeed read that study; wherein, as you have correctly stated the study does indeed suggest
"a low probability of neurotoxicity at nootropic doses", but you will note it does NOT suggest an
impossibility Whilst it is to an extent reassuring that the duration of elevation of Ca++ and subsequent increase of CA++ INFLUX is relatively short-lived; however, it occurs none the less, and hence there still exists the POSSIBILITY of EXCITOTOXICITY, even though the extent is very much reduced as compared with other substances such as SUNIFIRAM; and is certainly absolutely dosage dependant
Consequently, personally I would recommend one ascertains what is the minimum dosage that yields the desired therapeutic effects and avoid ramping up the dosage to the extent wherein the probability of manifestation of NEUROTOXICITY significantly increases
In short, CAUTION should be implemented when deciding on dosages for IDRA-21; as it has not been unknown for enthusiastic members of this forum to try out (on their lab rat) mega-doses and/or massively multiple repeat doses within a 24-hour period (e.g. 6 times per day); wherein, such actions in this particular instance would be ill advised due to IDRA-21's very much DOSAGE DEPENDANT potential for NEUROTOXICITY AND, as Yadayada so excellently stated, it is also advised that you "best not combine IDRA-21 with any other glutamate precursors or stimulants. Actually you would want to add some neuroprotective compound to be on the safe side"
Edited by ScienceGuy, 21 May 2013 - 04:34 AM.